arrow
S

Shanisha Gordon-Mitchell

montefiore einstein comprehensive cancer centre
H指数:12
被引数:1,069

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia

STAT3降解剂在Venetoclax耐药急性髓系白血病中显示出疗效

Leukemia
IF13.4
2026-02-170
OAAI
Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias

异质性白血病精准分析与治疗的剪接调控动力学

2025-05-070
PRE
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

谷氨酰胺酶抑制联合氮杂胞苷治疗骨髓增生异常综合征: 1b/2期临床试验及相关分析

2024-09-190
PRE
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency
2024-02-201
OAAI
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
2022-08-3040
OA
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer (vol 15, 70, 2022)
2022-07-260
OAAI
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer
2022-05-2316
OAAI
High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster
2022-03-0720
OA
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
2021-09-2139
OAAI
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts
2019-11-01126
OA
U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies

U2AF1突变在髓系恶性肿瘤中诱导致癌IRAK4亚型并激活先天免疫途径

2019-04-22170
OAAI
Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
2019-03-0467
OA
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells
2018-11-0569
OAAI
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia
2016-08-1434
OAAI